Equity Profile

CYTK

Cytokinetics, Incorporated

Health CareBiotechnology$10.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Cytokinetics, Incorporated (CYTK) is a biotechnology company focused on developing treatments for serious diseases related to muscle function. With a market cap of $11 billion, it operates in the health care sector, aiming to address unmet medical needs through innovative therapies.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is crucial as it reflects the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for signs of revenue growth to assess the demand for Cytokinetics' products and overall business momentum.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CYTK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-10.29%

Avg Stock Reaction

+3.00%

Last Quarter Recap

In Q1-2026, Cytokinetics reported an EPS of -$1.67, matching analyst expectations. The stock reacted positively, gaining 16.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for the upcoming earnings report are uncertain, with no analyst estimates available. Investors are keenly watching for any signs of improvement in financial performance.

Bull Case

An optimistic view suggests that if Cytokinetics can demonstrate strong revenue growth and manage to beat EPS expectations, it could lead to a significant stock rally.

Bear Case

Conversely, if the company fails to show progress in its product pipeline or reports disappointing financials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Cytokinetics' product pipeline and any upcoming clinical trial results?

The market will closely evaluate any updates on product development as it directly impacts future revenue potential.

How does management plan to address the recent financial performance and improve profitability?

Investors will look for clear strategies from management to enhance financial results, which could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cytokinetics' product pipeline to yield positive results, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 20.58% move, suggesting expectations for significant volatility that may not align with actual performance.

Cytokinetics has shown a history of surprising the market with better-than-expected results, as seen in previous quarters.

Key Risk

If the product pipeline shows promising results, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to translate its research into successful products and financial stability.

Bull Confirmed If

A clear indication of progress in clinical trials or new partnerships that could lead to increased revenue.

Bear Confirmed If

Failure to provide a positive outlook on product development or continued losses beyond expectations.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±19.6% while CYTK has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.5%

Calls (23K)P/C Ratio: 0.01Puts (12K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 15 of 30 (50%)

This setup has occurred 30 times across Health Care in the last 2 years. 15 of 30 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.9% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

18,449 sh

3 insiders

Net

$1.2M

Net selling

Most Active Insiders· 3 open-market trades

EVP, Chief Commercial OfficerCallos Andrew
$491,782.98

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cytokinetics beats expectations, history suggests the stock could rise by around 5.17%, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations but lack strong guidance, the stock may experience a muted reaction.

Miss

Should the company miss expectations, history indicates a potential decline of approximately 5.17%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any upcoming clinical trial results.
2Management's strategy for improving financial performance and profitability.
3Any new partnerships or collaborations that could enhance revenue potential.
4Insights into market demand for Cytokinetics' therapies.
5Guidance on future earnings expectations and growth outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is crucial as it reflects the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for signs of revenue growth to assess the demand for Cytokinetics' products and overall business momentum.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CYTK Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-10.29%

Avg Stock Reaction

+3.00%

Last Quarter Recap

In Q1-2026, Cytokinetics reported an EPS of -$1.67, matching analyst expectations. The stock reacted positively, gaining 16.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for the upcoming earnings report are uncertain, with no analyst estimates available. Investors are keenly watching for any signs of improvement in financial performance.

Bull Case

An optimistic view suggests that if Cytokinetics can demonstrate strong revenue growth and manage to beat EPS expectations, it could lead to a significant stock rally.

Bear Case

Conversely, if the company fails to show progress in its product pipeline or reports disappointing financials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Cytokinetics' product pipeline and any upcoming clinical trial results?

The market will closely evaluate any updates on product development as it directly impacts future revenue potential.

How does management plan to address the recent financial performance and improve profitability?

Investors will look for clear strategies from management to enhance financial results, which could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cytokinetics' product pipeline to yield positive results, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 20.58% move, suggesting expectations for significant volatility that may not align with actual performance.

Cytokinetics has shown a history of surprising the market with better-than-expected results, as seen in previous quarters.

Key Risk

If the product pipeline shows promising results, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to translate its research into successful products and financial stability.

Bull Confirmed If

A clear indication of progress in clinical trials or new partnerships that could lead to increased revenue.

Bear Confirmed If

Failure to provide a positive outlook on product development or continued losses beyond expectations.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±19.6% while CYTK has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.5%

Calls (23K)P/C Ratio: 0.01Puts (12K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 15 of 30 (50%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

18,449 sh

3 insiders

Net

$1.2M

Net selling

Most Active Insiders· 3 open-market trades

EVP, Chief Commercial OfficerCallos Andrew
$491,782.98

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cytokinetics beats expectations, history suggests the stock could rise by around 5.17%, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations but lack strong guidance, the stock may experience a muted reaction.

Miss

Should the company miss expectations, history indicates a potential decline of approximately 5.17%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any upcoming clinical trial results.
2Management's strategy for improving financial performance and profitability.
3Any new partnerships or collaborations that could enhance revenue potential.
4Insights into market demand for Cytokinetics' therapies.
5Guidance on future earnings expectations and growth outlook.